Bioinformatics Analysis of Inhibition Activation SHP-2 by Galangal as Activating Agent of Cancer Immunotherapy

Maria Indra Ardriyanto, Faaza Aulia Rahman, Hanaan Emilia Adi Hastuti, Edy Meiyanto, Taro Kawai, Dyaningtyas Dewi Pamungkas Putri


Interleukin 12 (IL-12) is a pro-inflammatory cytokine type 1 that has acted as a potential immunotherapy for cancer. The mechanism of IL-12 increases the activity of cytotoxic T cells and Natural Killer (NK) cells, reverse tumor-induced immunosuppression, prevent angiogenesis, and increases lymphocyte and antigen transport. Galangal is one of the natural ingredients that have biological activity as an anticancer and immunomodulator. In this research, researchers wanted to know the potential of the active compound of galangal to activate IL-12 by inhibiting the IL-12 analog, namely SHP-2. This research uses bioinformatics studies using several databases such as RCSB PDB, ChEMBL, Dr. Duke's Phytochemical and Ethnobotanical, UALCAN, OncoLnc and computational analysis using KNIME and MOE software. The SHP-2 structure used is taken from the RCSB PDB with the code 5EHR. The 10 compounds with the highest predictions of inhibiting SHP2 using KNIME were obtained, then molecular docking was performed using MOE and three compounds that had the potential to inhibit SHP-2 were Kaempferide, Galangin, and Riboflavin

Keywords: cancer, computing, galangal, Interleukin 12, SHP-2.

Full Text:



Abbas, A.K., Litchman, A.H., and Pober, J.S., 2016, Abbas’s Basic Immunology: Functions and Abnormalities of the Immune System, Fifth Edition, Elsevier.

Ahlina, F.N., Nugraheni, N., Salsabila, I.A., Haryanti, S., Da’i, M., and Meiyanto, E., 2020, Revealing the reversal effect of galangal (Alpinia galanga L.) extract against oxidative stress in metastatic breast cancer cells and normal fibroblast cells intended as a co-chemotherapeutic and anti-ageing agent, Asian Pacific Journal of Cancer Prevention, 21(1), 107-117. CrossRef

Alif, I., Utomo, R.Y., Ahlina, F.N., Nugraheni, N., Hermansyah, D., Putra, A., and Meiyanto, E., 2021, Immunopotentiation of galangal (Alpinia galanga L.) when combined with T-cells against metastatic triple-negative breast cancer, MDA-MB 231, Journal of Applied Pharmaceutical Science, 11(11), 053-061. CrossRef

Chansang, A., Champakaew, D., Junkum, A., Jitpakdi, A., Amornlerdpison, D., Aldred, A.K, et al., 2018, Synergy in Adulticidal Efficacy of Essential Oil for The Improvement of Permethrin Toxicity Against Aedes aegypti L. (Diptera: Culidae), Parasites and Vectors, 11(1), 417. CrossRef

Chouni, A., and Paul, S., 2018, A Review on Phytochemical and Pharmacological Potential of Alpinia galanga, PharmacogJ, 10(1), 9-15. CrossRef

Curiel, T.J., 2013, Cancer Immunotherapy: Paradigms, Practice and Promise, Springer, New York.

Dempke, W., Uciechowski, P., Fenchel, K., and Chevassut, T., 2018, Targeting SHP-1, 2 and SHIP pathways: a novel strategy for cancer treatment?, Oncology, 95(5), 257-269. CrossRef

Fallon, J., Tighe, R., Kradjian, G., Guzman, W., Bernhardt, A., Neuteboom, B., et al., 2014, The immunocytokine NHS-IL12 as a potential cancer therapeutic, Oncotarget, 5(7), 1869. CrossRef

Gettinger, S., Choi, J., Hastings, K., Truini, A., Datar, I., Sowell, R., et al., 2017, Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer, Cancer Discov., 7(12), 1420-1435.

Hamza, T., Barnett, J.B., and Li, B., 2010, Interleukin 12 a Key Immunoregulatory Cytokine in Infection Applications, Int J Mol Sci, 11(3), 789-806. CrossRef

Hasbiyani, N.A.F., Wulandari, F., Nugroho, E.P., Hermawan, A., and Meiyanto, E., 2021, Bioinformatics analysis confirms the target protein underlying mitotic catastrophe of 4T1 cells under combinatorial treatment of PGV-1 and galangin, Scientia Pharmaceutica, 89(3), 38. CrossRef

Jain, P.A., Pawar, R.J., Lodhi, S., and Singhai, A.K., 2012, Immunomodulatory and Anti-Oxidant Potential of Alpinia galanga Linn. Rhizomes, Pharmacognosy Communications, 2(3), 30-37. CrossRef

Kanumuri, R., Kumar Pasupuleti, S., Burns, S.S., Ramdas, B., and Kapur, R., 2022, Targeting SHP2 phosphatase in hematological malignancies, Expert Opinion on Therapeutic Targets, 1-14. CrossRef

Kumar, H., Kawai, T., and Akira, S., 2011, Pathogen Recognition by The Innate Immune System, International Reviews of Immunology, 30(1), 16-34. CrossRef

Nguyen, K.G., Vrabel, M.R., Mantooth, S.M., Hopkins, J.J., Wagner, E.S., Gabaldon, T.A., and Zaharoff, D.A., 2020, Localized Interleukin-12 for Cancer Immunotherapy, Frontiers in Immunology, 11, 575597. CrossRef

Putri, D.D.P., Kawasaki, T., Murase, M., Sueyoshi, T., Deguchi, T., Ori, D., Suetsugu, S., and Kawai, T., 2019, PtdIns3P phosphatases MTMR3 and MTMR4 negatively regulate innate immune responses to DNA through modulating STING trafficking, Journal of Biological Chemistry, 294(21), 8412-8423. CrossRef

Portielje, J.E., Gratama, J., van Ojik, H.H., Stoter, G., and Kruit, W.H., 2003. IL-12: a promising adjuvant for cancer vaccination, Cancer Immunology, Immunotherapy, 52, 133-144. CrossRef

Pratiwi, D.E., and Harjoko, A., 2013, Implementation of Face Recognition Using PCA (Principal Component Analysis), IJEIS, 3(2), 175-184.

Singh, D., Saini, A., Singh, R., and Agrawal, R., 2022, Galangin, as a Potential Anticancer Agent, Revista Brasileira de Farmacognosia, 32(3), 331-343. CrossRef

World Health Organization, 2018, Cancer, 11 February 2021. Retrieved February 11, 2021.

Xu, M., Mizoguchi, I, Morishima, N., Chiba, Y., Mizuguchi, J., and Yoshimoto, T., 2010, Regulation of Antitumor Immune Responses by the IL-12 Family Cytokines, IL-12, IL-23, and IL-27, Clinical and Developmental Immunology, 2010, 832454.


Copyright (c) 2023 Indonesian Journal of Cancer Chemoprevention

Indexed by:




Indonesian Society for Cancer Chemoprevention